Louis Williams

455 total citations
44 papers, 185 citations indexed

About

Louis Williams is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Louis Williams has authored 44 papers receiving a total of 185 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Hematology, 20 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Louis Williams's work include Multiple Myeloma Research and Treatments (28 papers), Protein Degradation and Inhibitors (8 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (6 papers). Louis Williams is often cited by papers focused on Multiple Myeloma Research and Treatments (28 papers), Protein Degradation and Inhibitors (8 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (6 papers). Louis Williams collaborates with scholars based in United States, United Kingdom and China. Louis Williams's co-authors include Faiz Anwer, Jack Khouri, Gareth J. Morgan, Jason Valent, Eileen M. Boyle, Danai Dima, Christy Samaras, Faith E. Davies, Lynn C. Moscinski and Maher Abdul‐Hay and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Louis Williams

37 papers receiving 183 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Louis Williams United States 9 110 84 67 29 22 44 185
Zoé Van de Wyngaert France 8 138 1.3× 81 1.0× 68 1.0× 26 0.9× 25 1.1× 22 191
Rabin Niroula United States 6 120 1.1× 119 1.4× 58 0.9× 35 1.2× 44 2.0× 23 284
Holly Lee Canada 9 100 0.9× 99 1.2× 94 1.4× 24 0.8× 15 0.7× 37 187
Patric Teodorescu Romania 10 90 0.8× 64 0.8× 44 0.7× 33 1.1× 42 1.9× 30 186
Lukas M. Braun Germany 9 67 0.6× 63 0.8× 53 0.8× 43 1.5× 28 1.3× 11 172
Kota Yoshifuji Japan 6 57 0.5× 111 1.3× 53 0.8× 11 0.4× 25 1.1× 28 208
Cinnie Yentia Soekojo Singapore 10 176 1.6× 202 2.4× 110 1.6× 43 1.5× 28 1.3× 30 298
Magdalena Sierra Spain 7 135 1.2× 126 1.5× 70 1.0× 15 0.5× 64 2.9× 14 236
Chantiya Chanswangphuwana Thailand 8 104 0.9× 36 0.4× 69 1.0× 35 1.2× 21 1.0× 36 168
Julia Krzykalla Germany 8 63 0.6× 54 0.6× 93 1.4× 21 0.7× 19 0.9× 17 195

Countries citing papers authored by Louis Williams

Since Specialization
Citations

This map shows the geographic impact of Louis Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Louis Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Louis Williams more than expected).

Fields of papers citing papers by Louis Williams

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Louis Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Louis Williams. The network helps show where Louis Williams may publish in the future.

Co-authorship network of co-authors of Louis Williams

This figure shows the co-authorship network connecting the top 25 collaborators of Louis Williams. A scholar is included among the top collaborators of Louis Williams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Louis Williams. Louis Williams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dima, Danai, Fauzia Ullah, Beth Faiman, et al.. (2025). Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14‐Year Experience of an Academic Center. Hematological Oncology. 43(3). e70082–e70082.
2.
Samaras, Christy, Akriti Jain, Jason Valent, et al.. (2025). Patients with multiple myeloma and CKD: Should we really hold off on bispecific therapy in this subgroup?. Blood. 146(Supplement 1). 2248–2248.
3.
Raza, Shahzad, Christy Samaras, Beth Faiman, et al.. (2024). Impact of T-Cell Redirecting Therapies on Survival Outcomes in Ultra-High-Risk Multiple Myeloma and Plasma Cell Leukemia. Blood. 144(Supplement 1). 7092–7092. 1 indexed citations
4.
Dima, Danai, James A. Davis, Leyla Shune, et al.. (2024). Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa‐1 trial eligibility criteria: A real‐world multicentre study. British Journal of Haematology. 204(4). 1293–1299. 10 indexed citations
5.
Dima, Danai, Mathias Schlögl, Jack Khouri, et al.. (2024). Role of Palliative Care in the Supportive Management of AL Amyloidosis—A Review. Journal of Clinical Medicine. 13(7). 1991–1991. 1 indexed citations
6.
Xu, Xuan, Shahzad Raza, Jim E. Riviere, et al.. (2023). Identification of genes encoding targets associated with adverse events in multiple myeloma.. Journal of Clinical Oncology. 41(16_suppl). 1556–1556. 2 indexed citations
7.
Patel, Meera, et al.. (2023). Intravenous immunoglobulin prophylaxis is associated with decreased rate of infection‐related hospitalizations in multiple myeloma patients. Hematological Oncology. 41(4). 718–724. 3 indexed citations
8.
Dima, Danai, Fauzia Ullah, Louis Williams, et al.. (2023). Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice. Cancers. 15(7). 2160–2160. 16 indexed citations
9.
Xu, Xuan, Majid Jaberi‐Douraki, Faiz Anwer, et al.. (2023). A novel risk assessment metric for antimyeloma therapies and drug interactions.. Journal of Clinical Oncology. 41(16_suppl). e24082–e24082. 2 indexed citations
10.
Braunstein, Marc, Louis Williams, David Kaminetzky, et al.. (2022). Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients. Leukemia. 36(3). 613–624. 17 indexed citations
11.
Ashby, Cody, Eileen M. Boyle, Michael Bauer, et al.. (2022). Structural variants shape the genomic landscape and clinical outcome of multiple myeloma. Blood Cancer Journal. 12(5). 85–85. 10 indexed citations
12.
Li, Hong, Faiz Anwer, Beth Faiman, et al.. (2022). Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma. Blood. 140(Supplement 1). 4290–4291. 1 indexed citations
13.
Boyle, Eileen M., Patrick Blaney, Yubao Wang, et al.. (2021). Unifying the Definition of High-Risk in Multiple Myeloma. Blood. 138(Supplement 1). 2714–2714.
14.
Maura, Francesco, Eileen M. Boyle, Even H Rustad, et al.. (2021). Chromothripsis as a pathogenic driver of multiple myeloma. Seminars in Cell and Developmental Biology. 123. 115–123. 25 indexed citations
15.
Ghamlouch, Hussein, Eileen M. Boyle, Patrick Blaney, et al.. (2021). Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer. Journal of Experimental & Clinical Cancer Research. 40(1). 380–380. 8 indexed citations
16.
Williams, Louis, et al.. (2020). Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation. Frontiers in Immunology. 11. 636–636. 22 indexed citations
17.
Morgan, Gareth J. & Louis Williams. (2020). Antibody-based targeting of BCMA in multiple myeloma. The Lancet Oncology. 21(2). 186–187. 2 indexed citations
18.
Williams, Louis, et al.. (2019). Genetic Segmentation and Targeted Therapeutics for Multiple Myeloma. 15(2). 87–87.
19.
Shen, Wenyi, Cassandra M. Hirsch, Bartlomiej Przychodzen, et al.. (2018). Heterozygous CTC1 Variants in Acquired Bone Marrow Failure. Blood. 132(Supplement 1). 3866–3866. 1 indexed citations
20.
Williams, Louis & Lynn C. Moscinski. (1993). Sterile transcription of immunoglobulin/T-cell receptor genes and other evidence of early lymphoid differentiation in acute myelogenous leukemia.. PubMed. 7(9). 1423–31. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zoé Van de Wyngaert Breakdown of academic impact, for papers by Rabin Niroula Breakdown of academic impact, for papers by Holly Lee Breakdown of academic impact, for papers by Patric Teodorescu Breakdown of academic impact, for papers by Lukas M. Braun Breakdown of academic impact, for papers by Kota Yoshifuji Breakdown of academic impact, for papers by Cinnie Yentia Soekojo Breakdown of academic impact, for papers by Magdalena Sierra Breakdown of academic impact, for papers by Chantiya Chanswangphuwana Breakdown of academic impact, for papers by Julia Krzykalla
Rankless by CCL
2026